BR112023024822A2 - Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b - Google Patents
Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células bInfo
- Publication number
- BR112023024822A2 BR112023024822A2 BR112023024822A BR112023024822A BR112023024822A2 BR 112023024822 A2 BR112023024822 A2 BR 112023024822A2 BR 112023024822 A BR112023024822 A BR 112023024822A BR 112023024822 A BR112023024822 A BR 112023024822A BR 112023024822 A2 BR112023024822 A2 BR 112023024822A2
- Authority
- BR
- Brazil
- Prior art keywords
- bcma
- cell
- target
- lymphomas
- redirecting antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163194470P | 2021-05-28 | 2021-05-28 | |
| US202163209694P | 2021-06-11 | 2021-06-11 | |
| PCT/EP2022/064362 WO2022248642A1 (en) | 2021-05-28 | 2022-05-26 | Bcma as a target for t cell redirecting antibodies in b cell lymphomas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024822A2 true BR112023024822A2 (pt) | 2024-02-20 |
Family
ID=82115891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024822A BR112023024822A2 (pt) | 2021-05-28 | 2022-05-26 | Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220411525A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4347039A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240014482A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119679935A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022281104A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024822A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3221399A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014139A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022248642A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116249548A (zh) | 2020-05-11 | 2023-06-09 | 詹森生物科技公司 | 用于治疗多发性骨髓瘤的方法 |
| EP4426437A4 (en) | 2021-11-03 | 2025-09-17 | Janssen Biotech Inc | METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI811023B (zh) | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| WO2021092060A1 (en) * | 2019-11-05 | 2021-05-14 | Engmab Sarl | Methods of treatment |
-
2022
- 2022-05-26 KR KR1020237044376A patent/KR20240014482A/ko active Pending
- 2022-05-26 US US17/825,123 patent/US20220411525A1/en not_active Abandoned
- 2022-05-26 BR BR112023024822A patent/BR112023024822A2/pt not_active Application Discontinuation
- 2022-05-26 CA CA3221399A patent/CA3221399A1/en active Pending
- 2022-05-26 WO PCT/EP2022/064362 patent/WO2022248642A1/en not_active Ceased
- 2022-05-26 EP EP22731534.8A patent/EP4347039A1/en active Pending
- 2022-05-26 AU AU2022281104A patent/AU2022281104A1/en not_active Abandoned
- 2022-05-26 MX MX2023014139A patent/MX2023014139A/es unknown
- 2022-05-26 JP JP2023573168A patent/JP2024519545A/ja active Pending
- 2022-05-26 CN CN202411436609.3A patent/CN119679935A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022248642A1 (en) | 2022-12-01 |
| US20220411525A1 (en) | 2022-12-29 |
| CA3221399A1 (en) | 2022-12-01 |
| CN119679935A (zh) | 2025-03-25 |
| EP4347039A1 (en) | 2024-04-10 |
| KR20240014482A (ko) | 2024-02-01 |
| MX2023014139A (es) | 2023-12-13 |
| JP2024519545A (ja) | 2024-05-15 |
| AU2022281104A1 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| BR112016029492A2 (pt) | método para tratamento de linfoma não hodgkin | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| MX2021006347A (es) | Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2. | |
| BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
| CY1123240T1 (el) | Αντισωμα αντι fgf23 και μια φαρμακευτικη συνθεση που το περιλαμβανει | |
| BRPI0617159B8 (pt) | compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo | |
| BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
| BRPI0617165B1 (pt) | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| BR112023014898A2 (pt) | Quinolinas e azaquinolinas como inibidores de cd38 | |
| ECSP088762A (es) | Tratamiento del dolor | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| EA201590709A1 (ru) | Комбинированная терапия и ее применение для лечения димиелинизирующих расстройств | |
| BR112015024621A8 (pt) | usos de dose unitária de unidades formadoras de colônia de c. novyi, composição farmacêutica compreendendo a referida dose unitária, kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano e dose unitária de unidades formadoras de colônia de c. novyi | |
| MX2020011817A (es) | Metodos para tratar el linfoma. | |
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases | |
| MX2021004819A (es) | Composiciones y metodos para tratar lesiones cerebrales. | |
| BR112022025105A2 (pt) | Método para o tratamento de câncer cervical em um indivíduo, conjugado anticorpo-fármaco, e, uso de um conjugado anticorpo-fármaco | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| BR112017018758A2 (pt) | alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide | |
| WO2019136157A3 (en) | Reducing beta-catenin and ido expression to potentiate immunotherapy | |
| MX2023014139A (es) | Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b. | |
| BR112022018948A2 (pt) | Métodos de tratamento de lesão pulmonar com inibidores de cgrp | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: JANSSEN BIOTECH, INC. (US) ; STICHTING AMSTERDAM UMC (NL) |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |